{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T03:32:11Z","timestamp":1772508731641,"version":"3.50.1"},"reference-count":59,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,3,30]],"date-time":"2023-03-30T00:00:00Z","timestamp":1680134400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Gynecological cancers are the most lethal malignancies among females, most of which are associated with gene mutations. Few studies have compared the differences in the genomic landscape among various types of gynecological cancers. In this study, we evaluated the diversity of mutations in different gynecological cancers.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A total of 184 patients with gynecological cancer, including ovarian, cervical, fallopian tube, and endometrial cancer, were included. Next-generation sequencing was performed to detect the mutations and tumor mutational burden (TMB). Kyoto Encyclopedia of Genes and Genomes (KEGG) and Gene Ontology (GO) enrichment analyses were also conducted.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We found that 94.57% of patients had at least one mutation, among which single nucleotide variants, insertions and InDels were in the majority. <jats:italic>TP53, PIK3CA, PTEN, KRAS, BRCA1, BRCA2, ARID1A, KMT2C, FGFR2<\/jats:italic>, and <jats:italic>FGFR3<\/jats:italic> were the top 10 most frequently mutated genes. Patients with ovarian cancer tended to have higher frequencies of <jats:italic>BRCA1<\/jats:italic> and <jats:italic>BRCA2<\/jats:italic> mutations, and the frequency of germline <jats:italic>BRCA1<\/jats:italic> mutations (18\/24, 75.00%) was higher than that of <jats:italic>BRCA2<\/jats:italic> (11\/19, 57.89%). A new mutation hotspot in <jats:italic>BRCA2<\/jats:italic> (I770) was firstly discovered among Chinese patients with gynecological cancer. Patients with <jats:italic>TP53<\/jats:italic>, <jats:italic>PIK3CA<\/jats:italic>, <jats:italic>PTEN<\/jats:italic>, and <jats:italic>FGFR3<\/jats:italic> mutations had significantly higher TMB values than those with wild-type genes. A significant cross was discovered between the enriched KEGG pathways of gynecological and breast cancers. GO enrichment revealed that the mutated genes were crucial for the cell cycle, neuronal apoptosis, and DNA repair.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Various gynecological cancer types share similarities and differences both in clinical characterization and genomic mutations. Taken together with the results of TMB and enriched pathways, this study provided useful information on the molecular mechanism underlying gynecological cancers and the development of targeted drugs and precision medicine.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2023.1143876","type":"journal-article","created":{"date-parts":[[2023,3,30]],"date-time":"2023-03-30T06:13:13Z","timestamp":1680156793000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Clinical characterization and genomic landscape of gynecological cancers among patients attending a Chinese hospital"],"prefix":"10.3389","volume":"13","author":[{"given":"Cen","family":"Jiang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiyi","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hua","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gang","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhao","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiwei","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,3,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.967633","article-title":"PARP inhibitor resistance in breast and gynecological cancer: Resistance mechanisms and combination therapy strategies","volume":"13","author":"Wang","year":"2022","journal-title":"Front Pharmacol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2019.01.027","article-title":"Large-Scale meta-analysis of mutations identified in panels of breast\/ovarian cancer-related genes - providing evidence of cancer predisposition genes","volume":"153","author":"Suszynska","year":"2019","journal-title":"Gynecol Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"4037","DOI":"10.3390\/cancers14164037","article-title":"Dendritic cell vaccines: A promising approach in the fight against ovarian cancer","volume":"14","author":"Caro","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B4","doi-asserted-by":"publisher","first-page":"63","DOI":"10.21037\/cco-20-4","article-title":"Breast cancer (BRCA) gene testing in ovarian cancer","volume":"9","author":"Chelariu-Raicu","year":"2020","journal-title":"Chin Clin Oncol"},{"key":"B5","unstructured":"2019"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1148\/rg.313105066","article-title":"Histologic, molecular, and cytogenetic features of ovarian cancers: Implications for diagnosis and treatment","volume":"31","author":"Lalwani","year":"2011","journal-title":"Radiographics"},{"key":"B7","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.792003","article-title":"Genomic profiling of Chinese cervical cancer patients reveals prevalence of DNA damage repair gene alterations and related hypoxia feature","volume":"11","author":"Wen","year":"2022","journal-title":"Front Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.928560","article-title":"Recommendations for the prevention, screening, diagnosis, staging, and management of cervical cancer in areas with limited resources: Report from the international gynecological cancer society consensus meeting","volume":"12","author":"Maluf","year":"2022","journal-title":"Front Oncol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21654","article-title":"Cancer statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30677-0","article-title":"Cancer incidence and mortality among young adults aged 20-39 years worldwide in 2012: a population-based study","volume":"18","author":"Fidler","year":"2017","journal-title":"Lancet Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32470-X","article-title":"Cervical cancer","volume":"393","author":"Cohen","year":"2019","journal-title":"Lancet"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3399\/bjgp22X720197","article-title":"Cervical screening: The evolving landscape","volume":"72","author":"Davies-Oliveira","year":"2022","journal-title":"Br J Gen Pract"},{"key":"B14","doi-asserted-by":"publisher","first-page":"870","DOI":"10.21037\/atm-22-3446","article-title":"A new strategy in molecular typing: the accuracy of an NGS panel for the molecular classification of endometrial cancers","volume":"10","author":"Li","year":"2022","journal-title":"Ann Transl Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B16","doi-asserted-by":"publisher","first-page":"5848","DOI":"10.3390\/cancers13225848","article-title":"Risk stratification of endometrial cancer patients: FIGO stage, biomarkers and molecular classification","volume":"13","author":"Kasius","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-019-0177-x","article-title":"Clinical actionability of molecular targets in endometrial cancer","volume":"19","author":"Urick","year":"2019","journal-title":"Nat Rev Cancer"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol29030172","article-title":"Risk-reducing options for high-grade serous gynecologic malignancy in BRCA1\/2","volume":"29","author":"Clarfield","year":"2022","journal-title":"Curr Oncol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e29","DOI":"10.3802\/jgo.2022.33.e29","article-title":"Genomic landscape of advanced endometrial cancer analyzed by targeted next-generation sequencing and the cancer genome atlas (TCGA) dataset","volume":"33","author":"Hong","year":"2022","journal-title":"J Gynecol Oncol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s12967-021-02722-8","article-title":"Circulating tumor DNA as a prognostic marker in high-risk endometrial cancer","volume":"19","author":"Feng","year":"2021","journal-title":"J Transl Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.18.00662","article-title":"Fallopian tube carcinoma","volume":"15","author":"Stasenko","year":"2019","journal-title":"J Oncol Pract"},{"key":"B22","doi-asserted-by":"publisher","first-page":"581","DOI":"10.3390\/medicina58050581","article-title":"Primary fallopian tube carcinoma presenting with a massive inguinal tumor: A case report and literature review","volume":"58","author":"Maeda","year":"2022","journal-title":"Medicina (Kaunas)"},{"key":"B23","doi-asserted-by":"publisher","first-page":"2660","DOI":"10.1038\/s41467-020-16432-0","article-title":"Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids","volume":"11","author":"L\u00f5hmussaar","year":"2020","journal-title":"Nat Commun"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2018.01.030","article-title":"Trends in the incidence of serous fallopian tube, ovarian, and peritoneal cancer in the US","volume":"149","author":"Liao","year":"2018","journal-title":"Gynecol Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2018.29.e43","article-title":"Prevalence of germline BRCA mutations among women with carcinoma of the peritoneum or fallopian tube","volume":"29","author":"Choi","year":"2018","journal-title":"J Gynecol Oncol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"8113","DOI":"10.3390\/ijerph19138113","article-title":"Epithelial ovarian cancer: Providing evidence of predisposition genes","volume":"19","author":"Shah","year":"2022","journal-title":"Int J Environ Res Public Health"},{"key":"B27","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.ygyno.2010.05.011","article-title":"Prevalence of BRCA1 and BRCA2 germ line mutations among women with carcinoma of the fallopian tube","volume":"118","author":"Vicus","year":"2010","journal-title":"Gynecol Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00073-5","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"22","author":"Poveda","year":"2021","journal-title":"Lancet Oncol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1186\/s12920-022-01376-9","article-title":"Genomic landscape, immune characteristics and prognostic mutation signature of cervical cancer in China","volume":"15","author":"Liu","year":"2022","journal-title":"BMC Med Genomics"},{"key":"B30","doi-asserted-by":"publisher","first-page":"13129","DOI":"10.3390\/ijms232113129","article-title":"Integrative genomic tests in clinical oncology","volume":"23","author":"Imyanitov","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.7150\/thno.51243","article-title":"Utilization of circulating cell-free DNA profiling to guide first-line chemotherapy in advanced lung squamous cell carcinoma","volume":"11","author":"Jiang","year":"2021","journal-title":"Theranostics"},{"key":"B32","volume-title":"Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM","author":"Li","year":"2013"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkw227","article-title":"VarDict: a novel and versatile variant caller for next-generation sequencing in cancer research","volume":"44","author":"Lai","year":"2016","journal-title":"Nucleic Acids Res"},{"key":"B34","volume-title":"Haplotype-based variant detection from short-read sequencing","author":"Garrison","year":"2012"},{"key":"B35","doi-asserted-by":"publisher","first-page":"e164","DOI":"10.1093\/nar\/gkq603","article-title":"ANNOVAR: Functional annotation of genetic variants from high-throughput sequencing data","volume":"38","author":"Wang","year":"2010","journal-title":"Nucleic Acids Res"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkw971","article-title":"The ExAC browser: Displaying reference data information from over 60 000 exomes","volume":"45","author":"Karczewski","year":"2017","journal-title":"Nucleic Acids Res"},{"key":"B37","article-title":"The genome aggregation database (gnomAD)","author":"Karczewski KJ Francioli","year":"2017","journal-title":"MacArthur Lab"},{"key":"B38","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13073-017-0424-2","article-title":"Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden","volume":"9","author":"Chalmers","year":"2017","journal-title":"Genome Med"},{"key":"B39","doi-asserted-by":"publisher","first-page":"5528","DOI":"10.3390\/cancers14225528","article-title":"Recent imaging updates and advances in gynecologic malignancies","volume":"14","author":"Daoud","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.12688\/f1000research.126337.1","article-title":"Role of RAS signaling in ovarian cancer","volume":"11","author":"Therachiyil","year":"2022","journal-title":"F1000Res"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000031705","article-title":"BRCA2 gene mutation in cancer","volume":"101","author":"Xie","year":"2022","journal-title":"Med (Baltimore)"},{"key":"B42","doi-asserted-by":"publisher","first-page":"101105","DOI":"10.1016\/j.gore.2022.101105","article-title":"Germline pathogenic variants associated with ovarian cancer: A historical overview","volume":"44","author":"Johansen","year":"2022","journal-title":"Gynecol Oncol Rep"},{"key":"B43","doi-asserted-by":"publisher","first-page":"3156","DOI":"10.1038\/ncomms4156","article-title":"Integrated analysis of germline and somatic variants in ovarian cancer","volume":"5","author":"Kanchi","year":"2014","journal-title":"Nat Commun"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1038\/nature10166","article-title":"Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma","volume":"474","year":"2011","journal-title":"Nature"},{"key":"B45","doi-asserted-by":"publisher","first-page":"5968","DOI":"10.1038\/s41467-022-33359-w","article-title":"Human papillomavirus integration perspective in small cell cervical carcinoma","volume":"13","author":"Wang","year":"2022","journal-title":"Nat Commun"},{"key":"B46","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1186\/s12964-022-00999-w","article-title":"PTEN overexpression and nuclear \u03b2-catenin stabilization promote morular differentiation through induction of epithelial-mesenchymal transition and cancer stem cell-like properties in endometrial carcinoma","volume":"20","author":"Yokoi","year":"2022","journal-title":"Cell Commun Signal"},{"key":"B47","doi-asserted-by":"publisher","first-page":"e86","DOI":"10.3802\/jgo.2022.33.e86","article-title":"Overview of fuzuloparib in the treatment of ovarian cancer: Background and future perspective","volume":"33","author":"Li","year":"2022","journal-title":"J Gynecol Oncol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq628","article-title":"Chemosensitivity and outcome of BRCA1- and BRCA2-associated ovarian cancer patients after first-line chemotherapy compared with sporadic ovarian cancer patients","volume":"22","author":"Vencken","year":"2011","journal-title":"Ann Oncol"},{"key":"B49","first-page":"4","article-title":"Screening for founder and recurrent BRCA mutations in Hong Kong and US Chinese populations","author":"Kwong","year":"2018","journal-title":"Hong Kong Med J"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1007\/s10689-013-9622-2","article-title":"Novel and recurrent BRCA1\/BRCA2 mutations in early onset and familial breast and ovarian cancer detected in the program of genetic counseling in cancer of valencian community (eastern Spain)","volume":"12","author":"de Juan Jim\u00e9nez","year":"2013","journal-title":"Relationship Family phenotypes Mutat prevalence Fam Cancer"},{"key":"B51","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1186\/s12885-022-09943-0","article-title":"Germline variants profiling of BRCA1 and BRCA2 in Chinese hakka breast and ovarian cancer patients","volume":"22","author":"Zhang","year":"2022","journal-title":"BMC Cancer"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2012.20","article-title":"Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer","volume":"307","author":"Bolton","year":"2012","journal-title":"JAMA"},{"key":"B53","doi-asserted-by":"publisher","first-page":"e000705","DOI":"10.1136\/jitc-2020-000705","article-title":"SITC cancer immunotherapy resource document: A compass in the land of biomarker discovery","volume":"8","author":"Hu-Lieskovan","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1713444","article-title":"Tumor mutational burden and response rate to PD-1 inhibition","volume":"377","author":"Yarchoan","year":"2017","journal-title":"N Engl J Med"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-018-0312-8","article-title":"Tumor mutational load predicts survival after immunotherapy across multiple cancer types","volume":"51","author":"Samstein","year":"2019","journal-title":"Nat Genet"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.943389","article-title":"A novel tumor mutational burden-based risk model predicts prognosis and correlates with immune infiltration in ovarian cancer","volume":"13","author":"Wang","year":"2022","journal-title":"Front Immunol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-022-02277-y","article-title":"Genomic and TCR profiling data reveal the distinct molecular traits in epithelial ovarian cancer histotypes","volume":"41","author":"Zhu","year":"2022","journal-title":"Oncogene"},{"key":"B58","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s12943-021-01479-4","article-title":"On-treatment blood TMB as predictors for camrelizumab plus chemotherapy in advanced lung squamous cell carcinoma: Biomarker analysis of a phase III trial","volume":"21","author":"Jiang","year":"2022","journal-title":"Mol Cancer"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13753","article-title":"Clinicopathologic and genomic characterization of PD-L1 positive urothelial carcinomas","volume":"26","author":"Huang","year":"2021","journal-title":"Oncologist"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1143876\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,30]],"date-time":"2023-03-30T06:13:24Z","timestamp":1680156804000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1143876\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,30]]},"references-count":59,"alternative-id":["10.3389\/fonc.2023.1143876"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2023.1143876","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,30]]},"article-number":"1143876"}}